NewAmsterdam Pharma Company N.V. Accounts Payable and Other Accrued Liabilities, Current
NewAmsterdam Pharma Company N.V. (NAMS) had Accounts Payable and Other Accrued Liabilities, Current of $10.28 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Payables and Accruals
us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent · last filed 2026-08-05
- 2026-06-30: Accounts Payable and Other Accrued Liabilities, Current $10.28M.
- 2026-03-31: Accounts Payable and Other Accrued Liabilities, Current $5.09M.
- 2025-12-31: Accounts Payable and Other Accrued Liabilities, Current $15.42M.
- 2025-09-30: Accounts Payable and Other Accrued Liabilities, Current $10.10M.
| Period end | Accounts Payable and Other Accrued Liabilities, Current |
|---|---|
| 2026-06-30 | $10.28M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $5.09M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $15.42M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $10.10M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $9.46M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $8.02M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $13.61M 10-K · filed 2026-02-18 |
| 2024-09-30 | $10.58M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $10.19M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $9.97M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $11.40M 10-K · filed 2025-02-26 |
| 2022-12-31 | $6.12M 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |